2.79
0.11 (3.92%)
Previous Close | 2.68 |
Open | 2.68 |
Volume | 219,334 |
Avg. Volume (3M) | 1,899,582 |
Market Cap | 820,644,800 |
Price / Sales | 25.96 |
Price / Book | 0.800 |
52 Weeks Range | |
Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
Operating Margin (TTM) | -1,439.42% |
Diluted EPS (TTM) | -0.610 |
Quarterly Revenue Growth (YOY) | -1.40% |
Total Debt/Equity (MRQ) | 6.62% |
Current Ratio (MRQ) | 9.34 |
Operating Cash Flow (TTM) | -120.17 M |
Levered Free Cash Flow (TTM) | -105.58 M |
Return on Assets (TTM) | -13.26% |
Return on Equity (TTM) | -15.55% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Mixed |
Biotechnology (Global) | Mixed | Mixed | |
Stock | AbCellera Biologics Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | 3.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | -5.0 |
Technical Oscillators | 2.0 |
Average | -0.50 |
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 27.93% |
% Held by Institutions | 39.65% |
Ownership
Name | Date | Shares Held |
---|---|---|
Founders Fund Vii Management, Llc | 30 Jun 2024 | 3,773,530 |
Guardian Capital Advisors Lp | 30 Jun 2024 | 1,786,414 |
52 Weeks Range | ||
Price Target Range | ||
High | 12.00 (Stifel, 330.88%) | Buy |
Median | 8.00 (187.25%) | |
Low | 4.00 (Keybanc, 43.63%) | Buy |
Average | 8.00 (187.25%) | |
Total | 2 Buy | |
Avg. Price @ Call | 2.88 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Keybanc | 08 Jan 2025 | 4.00 (43.63%) | Buy | 3.03 |
Stifel | 05 Nov 2024 | 12.00 (330.88%) | Buy | 2.72 |
No data within this time range.
Date | Type | Details |
---|---|---|
13 Jan 2025 | Announcement | AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology |
21 Nov 2024 | Announcement | AbCellera to Present at Upcoming Investor Conferences in December and January |
07 Nov 2024 | Announcement | AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 |
04 Nov 2024 | Announcement | AbCellera Reports Q3 2024 Business Results |
22 Oct 2024 | Announcement | AbCellera to Present at Upcoming Investor Conferences in November 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |